Together with the positive Phase I/II mesothelioma trial, Targovax has introduced a preliminary design for its next trial. The new study will explore ONCOS-102 in triple combination with a checkpoint inhibitor (CPI) and standard chemotherapy. Although plans for the next study are still at a preliminary stage, there is potential for it to become a pivotal programme due to a high unmet need in mesothelioma. The private placement completed on the back of the trial results provides confidence tha
27 Jan 2020
Targovax - ONCOS-102 set for late-stage development
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Targovax - ONCOS-102 set for late-stage development
Together with the positive Phase I/II mesothelioma trial, Targovax has introduced a preliminary design for its next trial. The new study will explore ONCOS-102 in triple combination with a checkpoint inhibitor (CPI) and standard chemotherapy. Although plans for the next study are still at a preliminary stage, there is potential for it to become a pivotal programme due to a high unmet need in mesothelioma. The private placement completed on the back of the trial results provides confidence tha